Bristol/ImClone Pull, Will Resubmit, Erbitux sBLA For Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA questions whether tested batches of drug are comparable.
You may also be interested in...
Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
Bristol-Myers Squibb expects its next launch, diabetes drug Onglyza, along with its expanding string of "pearls" - partnership deals - will place the firm in a superior position to offset generic losses in 2012
Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
Bristol-Myers Squibb expects its next launch, diabetes drug Onglyza, along with its expanding string of "pearls" - partnership deals - will place the firm in a superior position to offset generic losses in 2012
FDA Agrees To Accelerated Approval For Myozyme Scale-Up, Genzyme Says
The 2,000L version of Myozyme on track for approval with a post-market confirmatory trial in February; user fee date extended while FDA reviews REMS submission.